Barely two months after being approved for Crohn's disease, the news for Tysabri continues to worsen. Three weeks ago, deadly melanomas were reported. Now the FDA has posted warnings about serious liver damage after a single dose. The manufacturers (Elan and Biogen) have sent letters directly to doctors involved in its use.
Yesterday's Washington Post carried the following news:
Similarly, the Wall Street Journal also covered the story:
Given Tysabri's history, including changing it's name after causing patient deaths and being pulled from the market in 2005, it seems that the FDA should immediately revoke it's approval for Crohn's disease.